Healthcare Equity
T. Rowe Price Health Sciences Equity Fund
Last updated: 2026-03-13
The Verdict
T. Rowe Price Health Sciences Equity Fund charges an expense ratio of 1.86%. On a $100,000 portfolio, that's $1,860 per year in fees. Supreme.PM's decoded model provides similar exposure at a fraction of the cost, potentially saving $1,610 per year.
Expense Ratio
1.86%
Star Rating
3/ 5
Market Beta
1.02
Supreme.PM Cost
0.25%
Annual platform fee
Fee Analysis
T. Rowe Price Health Sciences Equity Fund charges 1.86% annually. Supreme.PM offers equivalent exposure for 0.25%, a savings of 1.61 percentage points.
Data sources: Refinitiv Lipper, SEC EDGAR Filings, Supreme.PM Analytics
Past performance does not guarantee future results. Model returns are backtested and may not reflect actual trading conditions.
Related
Healthcare Equity Category
Browse all Healthcare Equity funds
Healthcare Equity Rankings
Top-rated Healthcare Equity funds
Our Methodology
How we decode fund strategies
AXA Framlington Health
2-star rated
Pictet-Health
1-star rated
Wellington Global Health Care Equity
2-star rated
Polar Capital Healthcare Opportunities
4-star rated
Invesco Global Health Care Innovation
2-star rated
Frequently Asked Questions
What is the expense ratio of T. Rowe Price Health Sciences Equity Fund?
T. Rowe Price Health Sciences Equity Fund has an expense ratio of 1.86%. Supreme.PM's decoded model provides similar exposure at a significantly lower cost.
How does Supreme.PM replicate T. Rowe Price Health Sciences Equity Fund?
Supreme.PM uses AI to analyze the fund's holdings and trading patterns, creating a decoded model that tracks the fund's performance.
What are the risks of fund replication?
While our models aim for high correlation, they may not perfectly match the fund's returns due to timing differences in rebalancing, transaction costs, and disclosure delays. Backtested results may not reflect future performance.
Get This Strategy
Start investing with Supreme.PM's decoded model and save on fees while capturing similar returns.